Candel Therapeutics adds Martine Zimmermann to board ahead of planned BLA filingSep 10Partnershipaglatimagene besadenovecCandel Therapeutics, Inc.
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.
Sign inSign in